Read the bottom half of this post for a history of Hope Medicine and Bayer’s HMI-115. This treatment targets the prolactin (PRL) receptor to cure hair loss. Hope Medicine raised $56 million in funding in 2021. Their pipeline page is worth monitoring.
The initial reason for all this excitement was due to the spectacular long-lasting hair growth results seen in stump-tailed macaque monkeys. Per the clinical trial participant I mention further below, these monkeys are still being monitored and have not lost their hair over four years after prolactin receptor antibody treatment.
Update: November 16, 2022 — A November 2, 2022 detailed Reddit update from a trial participant (dose 1 and dose 2) in Australia is required reading. This 37-year old guy had his first two doses (in one month) of the prolactin blocker via injection. He, along with his female partner (age 46) will get treatment every two weeks for six months. So a total of 12 doses, all at Sinclair Dermatology in Melbourne. Note that while these are Phase 1 trials in Australia, the same HMI-115 product is scheduled to undergo Phase 2 clinical trials in the US anytime soon.
This Redddit user moeman32 seems completely legitimate and has been on Reddit for over ten years. He has also posted about Australia many times in the past. We all owe him major respect. He will do follow-up posts every two weeks. Note that all 20 patients in this Phase 1 safety trial are getting the actual drug (i.e., no placebo needed to test efficacy this time around).
- First follow-up (dose 3).
- A really encouraging second follow-up (dose 4). His below quote with minor changes from me is very positive:
“The vortex existing hair has filled out much thicker and quicker. The frontal scalp is now growing dormant hair. The hairline has definitely moved 15mm forward and the hair is a few cm long (havent had a haircut since before the trial). All in all, it is making a visible difference to my hairline.”
- Third follow-up (dose 5). Another positive update.
Update: April 12, 2022 — For some reason, Australian Phase 1 trials for Hope Medicine’s HMI-115 are starting today. They will involve 20 participants and are expected to be completed in July 2023. The trials will be led by the renowned hair loss expert Dr. Rodney Sinclair. Also see his current clinical trials recruiting page hair section.
Update: April 14, 2022 — Lots of excitement on Reddit.
Meanwhile, US Phase 2 trials should start at any moment now (read further below). This difference in trial progression by country is very strange. Perhaps is has to do with some stricter Australian government requirements.
Update: January 26, 2022
Hope Medicine HMI-115 Phase 2 Trials
Hope Medicine just received FDA approval to commence Phase 2 clinical trials in the US for its HMI-115 product to treat androgenetic alopecia. HMI-115 is a human monoclonal antibody drug that targets the PRL receptor for the treatment of male and female pattern hair loss. Last year, the US FDA also approved Phase 2 trials of the same drug to treat endometriosis.
The Phase II clinical trial of HMI-115 for the treatment of androgenetic alopecia:
“Will be an international multi-center, randomized, double-blind, placebo-controlled study. It will be carried out in the United States, Australia and other countries.”
Update: November 28, 2021
New CEO Henri Doods Interview
A reader sent me the below screenshot of Hope Medicine CEO Henri Doods’ Chinese magazine interview that I mentioned earlier. If anyone can translate into English, please post in the comments. Click on the image to expand.
Update: September 20, 2021
Reader “Karl” just notified us that there is a brand new cover page interview of Hope Medicine’s CEO Dr. Henri Doods in a Chinese magazine “tradetree.cn”. If anyone can gain access to it (see here) and translate into English, please try. Not worth purchasing as yet in my opinion.
Per Karl, Phase 2 clinical trials for hair loss product HMI-115 are planned for Q4 2021 (but no proof anywhere else). This matches what we expected per the prior updates that I discussed in May (see further below). Note that HMI-115 is the same as Bayer’s prolactin receptor antibody. Hope Medicine has the rights to the development of this product.
May 9, 2021
Hope Medicine (China) Raises $56 Million
Until now, Kintor Pharmaceutical (China) was the main reason for recent excitement. However, this weekend, the participants on this site’s hair loss chat are discussing Hope Medicine. Out of the blue, this startup company received $56 million in a Series B round of financing. Investment firms Qiming Venture Partners and Grand Flight Investment led the way.
Other investors include: HighLight Capital; Sinovation Ventures (a venture capital firm led by former Google China head Kai-Fu Lee); and Trustbridge. More here.
HMI-115 PRL Receptor Targeting: Bayer License
“Previously, HopeMed signed an exclusive license agreement with Bayer AG on the development and commercialization of a human antibody (HMI-115) targeting the prolactin (PRL) receptor for the treatment of male and female pattern hair loss. At present, HMI-115 has completed phase I clinical trials in the European Union, with positive safety results. The global multi-center phase II clinical trials for androgenic alopecia and will soon be launched.“
Note that I first covered Hope Medicine in my 2019 post on its partnership with Bayer in regards to the prolactin receptor. The company was founded by Dr. Rui-Ping Xiao, the dean of the College of Future Technology of Peking University. Apparently, she is also an associate editor of the New England Journal of Medicine. Update: See this page for much more on Dr. Xiao Ruiping.
The most unusual part of this story is that Hope Medicine’s official website (hopemedinc.com) has not worked for weeks. I have e-mailed several of their employees, and will update this post if I get any response.